用于高钾血症临床管理的钾结合剂
Potassium-Binding Agents for the Clinical Management of Hyperkalemia.
作者信息
Chaitman Martin, Dixit Deepali, Bridgeman Mary Barna
出版信息
P T. 2016 Jan;41(1):43-50.
Abstract
Use of sodium polystyrene sulfonate (SPS) dominates the long-term treatment of hyperkalemia, but two new agents, sodium zirconium cyclosilicate and the recently FDA-approved patiromer, may offer potential advantages compared with SPS.
摘要
聚苯乙烯磺酸钠（SPS）的使用在高钾血症的长期治疗中占主导地位，但两种新药，环硅酸锆钠和最近获得美国食品药品监督管理局（FDA）批准的帕替罗姆，与SPS相比可能具有潜在优势。
相似文献
1
Potassium-Binding Agents for the Clinical Management of Hyperkalemia.用于高钾血症临床管理的钾结合剂
P T. 2016 Jan;41(1):43-50.
2
Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.帕替罗姆、环硅酸锆钠和聚苯乙烯磺酸钠治疗高钾血症的临床效用：一项循证综述
Core Evid. 2017 Mar 23;12:11-24. doi: 10.2147/CE.S129555. eCollection 2017.
3
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.用于慢性肾脏病患者慢性高钾血症的钾结合剂。
Cochrane Database Syst Rev. 2020 Jun 26;6(6):CD013165. doi: 10.1002/14651858.CD013165.pub2.
4
Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project.评估新型钾结合剂在常规护理中的应用；斯德哥尔摩肌酐测量（SCREAM）项目。
J Nephrol. 2024 May;37(4):961-972. doi: 10.1007/s40620-023-01860-0. Epub 2024 Jan 18.
5
Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.环硅酸锆钠（ZS-9）：一种治疗高钾血症的新型药物。
Pharmacotherapy. 2016 Aug;36(8):923-33. doi: 10.1002/phar.1797. Epub 2016 Aug 2.
6
Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients.住院患者高钾血症治疗中聚苯乙烯磺酸鈉和硅酸锆鈉的有效性和安全性比较。
Am J Health Syst Pharm. 2023 Sep 7;80(18):1238-1246. doi: 10.1093/ajhp/zxad137.
7
Patiromer for the treatment of hyperkalemia.聚普瑞锌用于高钾血症的治疗。
Expert Rev Clin Pharmacol. 2020 Jun;13(6):563-570. doi: 10.1080/17512433.2020.1774363. Epub 2020 Jun 8.
8
Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia.钾结合剂治疗慢性肾脏病伴高钾血症患者的疗效和安全性。
Eur J Pharmacol. 2022 Sep 15;931:175174. doi: 10.1016/j.ejphar.2022.175174. Epub 2022 Aug 12.
9
Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department.聚苯乙烯磺酸钠与环硅酸锆钠用于急诊科高钾血症治疗的比较
Am J Emerg Med. 2023 Mar;65:59-64. doi: 10.1016/j.ajem.2022.12.043. Epub 2022 Dec 27.
10
Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.环硅酸锆钠治疗慢性肾脏病相关高钾血症：一种新型药物。
Expert Rev Clin Pharmacol. 2021 Sep;14(9):1055-1064. doi: 10.1080/17512433.2021.1932460. Epub 2021 Jul 6.
引用本文的文献
1
Outcomes and Resource Utilization in Hyperkalemic Emergency Department Patients Treated With Patiromer or Sodium Zirconium Cyclosilicate.接受帕替罗姆或环硅锆酸钠治疗的高钾血症急诊科患者的治疗结果和资源利用情况
J Am Coll Emerg Physicians Open. 2025 May 10;6(4):100158. doi: 10.1016/j.acepjo.2025.100158. eCollection 2025 Aug.
2
Economic Evaluation of Patiromer in Patients with Concomitant Heart Failure and Chronic Kidney Disease in Italy.意大利伴心力衰竭和慢性肾脏病患者使用帕替罗姆的经济学评估
Pharmacoecon Open. 2025 May 12. doi: 10.1007/s41669-025-00581-3.
3
Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial.环硅酸锆钠与聚苯乙烯磺酸钠治疗血液透析患者高钾血症的随机临床试验
BMC Nephrol. 2025 May 6;26(1):227. doi: 10.1186/s12882-025-04129-9.
4
Effectiveness, safety, and treatment pattern of sodium zirconium cyclosilicate in Chinese patients with hyperkalemia: interim analysis from a multicenter, prospective, real-world study (Actualize Study).环硅酸锆钠在中国高钾血症患者中的有效性、安全性及治疗模式：一项多中心、前瞻性、真实世界研究（实际应用研究）的中期分析
Front Pharmacol. 2024 Jul 29;15:1398953. doi: 10.3389/fphar.2024.1398953. eCollection 2024.
5
The impact of nanomaterials on autophagy across health and disease conditions.纳米材料对健康和疾病状态下自噬的影响。
Cell Mol Life Sci. 2024 Apr 17;81(1):184. doi: 10.1007/s00018-024-05199-y.
6
Hyperkalemia: Pharmacotherapies and Clinical Considerations.高钾血症：药物治疗与临床考量
Cureus. 2024 Jan 26;16(1):e52994. doi: 10.7759/cureus.52994. eCollection 2024 Jan.
7
Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study.帕替罗默作为需要紧急血钾管理的患者的辅助治疗药物的效用（PLATINUM）：一项多中心、随机、双盲、安慰剂对照、平行组研究的设计。
BMJ Open. 2023 Jun 12;13(6):e071311. doi: 10.1136/bmjopen-2022-071311.
8
Assessment of potassium ion channel during electric signalling in biofilm formation of for finding antibiofilm molecule.在生物膜形成的电信号传导过程中评估钾离子通道以寻找抗生物膜分子。
Heliyon. 2023 Jan 5;9(1):e12837. doi: 10.1016/j.heliyon.2023.e12837. eCollection 2023 Jan.
9
The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings.医疗保险患者入住长期护理机构后高钾血症的临床和经济负担增加。
Adv Ther. 2023 Mar;40(3):1204-1223. doi: 10.1007/s12325-022-02420-x. Epub 2023 Jan 18.
10
Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia.机器学习模型预测高钾血症患者的心血管和肾脏结局及死亡率。
Nutrients. 2022 Nov 3;14(21):4614. doi: 10.3390/nu14214614.
本文引用的文献
1
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.聚磺苯乙烯钠散对高钾血症合并糖尿病肾病患者血钾水平的影响：AMEHTYST-DN 随机临床试验。
JAMA. 2015 Jul 14;314(2):151-61. doi: 10.1001/jama.2015.7446.
2
A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.一项针对慢性肾病患者高钾血症治疗的2期研究表明，选择性钾离子捕获剂ZS-9安全且有效。
Kidney Int. 2015 Aug;88(2):404-11. doi: 10.1038/ki.2014.382. Epub 2015 Feb 4.
3
Characterization of structure and function of ZS-9, a K+ selective ion trap.钾离子选择性离子阱ZS-9的结构与功能表征
PLoS One. 2014 Dec 22;9(12):e114686. doi: 10.1371/journal.pone.0114686. eCollection 2014.
4
Sodium zirconium cyclosilicate in hyperkalemia.硅酸锆钠治疗高钾血症。
N Engl J Med. 2015 Jan 15;372(3):222-31. doi: 10.1056/NEJMoa1411487. Epub 2014 Nov 21.
5
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.在接受 RAAS 抑制剂治疗的肾病和高钾血症患者中应用帕替络尔。
N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21.
6
Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.环硅酸锆钠降低高钾血症门诊患者血钾水平 28 天的疗效：HARMONIZE 随机临床试验。
JAMA. 2014 Dec 3;312(21):2223-33. doi: 10.1001/jama.2014.15688.
7
Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.使用聚苯乙烯磺酸纳（Kayexalate）的胃肠道不良事件：系统评价。
Am J Med. 2013 Mar;126(3):264.e9-24. doi: 10.1016/j.amjmed.2012.08.016. Epub 2013 Jan 12.
8
Management of hyperkalemia in hospitalized patients.住院患者高钾血症的管理。
Am J Med Sci. 2014 Feb;347(2):93-100. doi: 10.1097/MAJ.0b013e318279b105.
9
Interventions for non-oliguric hyperkalaemia in preterm neonates.早产儿非少尿性高钾血症的干预措施。
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD005257. doi: 10.1002/14651858.CD005257.pub3.
10
PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.PEARL-HF研究：使用新型聚合钾结合剂RLY5016预防心力衰竭患者高钾血症
Future Cardiol. 2012 Jan;8(1):17-28. doi: 10.2217/fca.11.71.
Zotero 插件